CD44 and breast carcinoma: We previously demonstrated that the anti-CD44 mAb, H4C4 [52, 57] stained all three tested tumorigenic cell lines, the breast cancer cell line MB-231, the melanoma cell line HTB-66, and the glioblastoma cell line U87 [14, 15].